Celecoxib (CXB) is a selective COX-2 inhibitor that has been demonstrated to help patients with BPH who experience nocturia (Falahatkar et al. 2008; Goodarzi et al. 2011). This evidence concerns the gene PTGS2 and benign prostatic hyperplasia.